Express . . . Novartis heavy IL-17A inhibitors have won the fourth FDA indication to treat mid-axis spinal arthritis.

▎ recently, Novartis announced that the US FDA has approved the expansion of cosentyx (secukinumab), a heavyweight IL-17A inhibitor, for the treatment of active non radiologic axial spondylitis (NR axspa).this is cosentyx's fourth indication approved by FDA.previously, it has been approved by FDA for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.axial spondyloarthritis (axspa) is a kind of spinal arthritis that affects the pelvic joint and spine. It can be manifested as chronic inflammatory back pain, spinal stiffness, and impaired bone function and mobility.in its most severe cases, inflammation can lead to new bone formation and fusion of spinal segments in a fixed fixed position.according to whether the sacroiliac joint injury can be detected by X-ray radiography, axspa can be divided into NR axspa and r-axspa.NR axspa is usually difficult to diagnose, and many patients are delayed in diagnosis and difficult to get proper treatment.cosentyx is the first whole human biological agent that can directly inhibit IL-17A.IL-17A is a core pathogenic factor involved in psoriasis, psoriatic arthritis, ankylosing spondylitis, and NR axspa, and plays a key role in the pathogenesis.cosentyx can specifically bind to any source of IL-17A without interfering with the normal operation of other cytokines.because of the precise target and the higher safety brought by the whole human antibody, the drug shows rapid and lasting efficacy and safety in the treatment of inflammatory diseases.cosentyx's approval is based on the efficacy and safety results of a phase 3 clinical study called present.the study included 555 adult patients with active NR axspa who received biological product therapy for the first time or did not respond to or tolerate anti-tumor necrosis factor - α therapy.the results of the trial showed that the proportion of patients who met the asas40 standard was significantly improved after 52 weeks of treatment compared with placebo.in addition, the questionnaire scores and other indicators for the quality of life and health status of the patients were also improved."the results from the present trial showed a significant decrease in disease activity in patients treated with cosentyx compared with placebo," said Atul deodhar, M.D., Professor of medicine at Oregon University of health and science and researcher of present clinical trials."this approval provides a new treatment option for patients with non radiologic axial spondylarthritis. "References: [1] Novartis cosentyx Receives FDA approval for new indication to treat active non-radiological axial spondyloarthritis. Retrieved June 16, 2020, from note: This paper aims to introduce the progress of medical and health research, not to recommend treatment options. if you need guidance on treatment plan, please go to a regular hospital.